Novel Anti-HSV Antibody

Abstract

Described is a (first) anti-HSV antibody or an antigen-binding fragment thereof binding to the glycoprotein B (gB) of HSV-1 and/or HSV-2, wherein said antibody comprises the complementarity determining regions VHCDR1, VHCDR3, VLCDR1, VLCDR2, and VLCDR3, each comprising the sequences as defined in the claims, wherein said antibody or antigen-binding fragment has a low dissociation rate kdis of at most 5.0×10−4 s−1, preferably at most 1.0×10−4 s−1, at most 5.0×10−5 s−1, and most preferably at most 2.9×10−5 s−1. Moreover, described is a combination of (A) said (first) anti-HSV antibody or an antigen-binding fragment thereof; and (B) a second anti-HSV antibody or an antigen-binding fragment thereof recognizing/binding to the glycoprotein B (gB) of the HSV-1 and/or HSV-2, wherein said antibody comprises the complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3, each comprising the sequences as defined in the claims, wherein said second antibody has a dissociation constant Kd of at most 40 nM, preferably at most 30 nM, more preferably at most 20 nM, even more preferably at most 15 nM, at most 13 nM and at most 10 nM. Further, described is a pharmaceutical composition comprising an effective amount of said anti-HSV antibody or the antigen-binding fragment thereof or the combination of said antibodies and at least one pharmaceutically acceptable excipient. Further, described is an anti-HSV antibody or the antigen-binding fragment thereof or said combination of said antibodies for use in a method for the prophylactical or therapeutical treatment of a disorder or disease as defined in the claims. Further, described is a bispecific antibody binding to the glycoprotein B (gB) of the HSV-1 and/or HSV-2 which comprises: (A) a first binding domain comprising: the complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 of the above first antibody; and (B) a second binding domain comprising: the complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 of the above second antibody; wherein said bispecific antibody has a low dissociation rate kdis of at most 5.0×10−4 s−1, preferably at most 1.0×10−4 s−1, at most 5.0×10−5 s−1, and most preferably at most 2.9×10−5 s−1. Finally, described is a trispecific antibody which, in addition to the first and second binding domain as described for the bispecific antibody, comprises a third binding domain.

Dependencies are inferred from the claim text.